Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia

被引:11
作者
Adamia, S
Treon, SP
Reiman, T
Tournilhac, O
McQuarrie, C
Mant, MJ
Belch, AR
Pilarski, LM
机构
[1] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[2] Univ Alberta, Dept Oncol, Edmonton, AB, Canada
[3] Univ Alberta, Dept Med, Edmonton, AB, Canada
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
来源
CLINICAL LYMPHOMA | 2005年 / 5卷 / 04期
关键词
exonic splicing enhancer; hyaluronan; splicing factor;
D O I
10.3816/CLM.2005.n.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The hyaluronan synthase 1 (HAS1) gene encodes a plasma membrane protein that synthesizes hyaluronan, an extracellular matrix molecule. Previously, in patients with Waldenstrom's macroglobulinemia (WM), we detected upregulation of HAS1 transcripts and identified aberrant splice variants of this gene. Aberrant splicing of HAS1 results from activation of cryptic splice sites. In turn, activation of cryptic donor and acceptor splice sites can be promoted by mutations occurring upstream of these sites and/or at the branch point of slicing. We measured the frequency of the HAS1 833A/G polymorphism (ie, single-nucleotide polymorphism; SNP) in patients with WM and healthy donors. Additionally, HAS1 gene expression was evaluated in the same group of patients. Our observations so far suggest that HAS1 833A/G Ills contribute to aberrant splicing of this gene; this idea is supported by the fact that MING SIP is located on an exonic splicing enhancer motif. Based on the results obtained thus far, we speculate that individuals with HAS1 833G/G genotype are predisposed toward aberrant HAS1 splicing and expression of HAS1 variants, resulting in an enhanced risk of developing WM. Study of a larger group of patients and healthy donors is needed to confirm these speculations and to evaluate the prognostic significance of these findings.
引用
收藏
页码:253 / 256
页数:4
相关论文
共 34 条
[1]  
Adamia S, 2003, BLOOD, V102, p371B
[2]   Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulimenia [J].
Adamia, S ;
Crainie, M ;
Kriangkum, J ;
Mant, MJ ;
Belch, AR ;
Pilarski, LM .
SEMINARS IN ONCOLOGY, 2003, 30 (02) :165-168
[3]  
Adamia S, 2001, BLOOD, V98, p373A
[4]  
ADAMIA S, 2005, IN PRESS BLOOD
[5]   Alternative and aberrant splicing of MDM2 mRNA in human cancer [J].
Bartel, F ;
Taubert, H ;
Harris, LC .
CANCER CELL, 2002, 2 (01) :9-15
[6]  
Blanchette M, 1997, RNA, V3, P405
[7]   Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases [J].
Blencowe, BJ .
TRENDS IN BIOCHEMICAL SCIENCES, 2000, 25 (03) :106-110
[8]   Alternative spliced transcripts as cancer markers [J].
Caballero, OL ;
de Souza, SJ ;
Brentani, RR ;
Simpson, AJG .
DISEASE MARKERS, 2001, 17 (02) :67-75
[9]   Alternative splicing:: multiple control mechanisms and involvement in human disease [J].
Cáceres, JF ;
Kornblihtt, AR .
TRENDS IN GENETICS, 2002, 18 (04) :186-193
[10]   Correction of disease-associated exon skipping by synthetic exon-specific activators [J].
Cartegni, L ;
Krainer, AR .
NATURE STRUCTURAL BIOLOGY, 2003, 10 (02) :120-125